MétaCan
Menu
Back to cohort

Abstract A119: Investigating PIK3CA mutational status on cisplatin and radiation sensitivity in cervical cancer cell lines: Implications for PI3K inhibitor therapy

2015· article· en· W2397178591 on OpenAlexaff
Wani Arjumand, Cole D. Merry, Chen Wang, Shujuan Fang, Elizabeth Kornaga, Jb McIntyre, Prafull Ghatage, Martin Köbel, Corinne Doll, Susan P. Lees‐Miller

Bibliographic record

VenueMolecular Cancer Therapeutics · 2015
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicPI3K/AKT/mTOR signaling in cancer
Canadian institutionsSAIT PolytechnicUniversity of Calgary
Fundersnot available
KeywordsCisplatinPI3K/AKT/mTOR pathwayCancer researchHeLaCervical cancerMedicineCancerRadiation therapyMutationChemotherapyCell cultureMolecular biologyBiologyInternal medicineGeneSignal transductionGenetics

Abstract

fetched live from OpenAlex

Abstract The phosphatidylinositol-3 kinase (PI3K)/AKT/ mTOR signaling pathway is activated in many different human cancers. Activation is frequently mediated by “hotspot” mutations including E542K, E545K and H1047R in the PIK3CA gene, which encodes the catalytic subunit of PI3Kα. We previously reported PIK3CA mutation in patients with early stage (IB/II) cervical cancer was associated with poor survival (McIntyre et al. Gynecol Oncol. 2013, 128(3): 409-14). The purpose of this study was to determine whether PIK3CA mutation renders cervical cancer cells more resistant to conventional therapy (cisplatin chemotherapy and/or radiation), and whether PI3K inhibition enhances cell kill and/or reverse this phenotype. Here, we report that the cervical cancer cell line CaSki, which expresses the PIK3CA-E545K mutation, is more resistant to cisplatin than cervical cancer cells with wild-type PIK3CA. To validate our findings, we depleted endogenous PIK3CA from HeLa cells using shRNA and stably expressed either shRNA resistant wild-type PIK3CA or PIK3CA-E545K. Cells expressing PIK3CA-E545K were more resistant to cisplatin and cisplatin plus ionizing radiation than cells expressing either wild-type PIK3CA or lacking PIK3CA. Preliminary results also suggest that cells expressing PIK3CA-E545K have an enhanced migratory phenotype. We are currently testing whether treatment with the PI3K inhibitor GDC-0941 restores sensitivity to cisplatin and reverts this aggressive phenotype. Together, these experiments will determine whether inhibition of the PI3K pathway in cervical cancers with PIK3CA activating mutation has potential for therapeutic benefit. Citation Format: ARJUMAND WANI, COLE MERRY, CHEN WANG, SHUJUAN FANG, ELIZABETH KORNAGA, Jb MCINTYRE, PRAFULL GHATAGE, MARTIN KöBEL, CORINNE M. DOLL, SUSAN P. LEES-MILLER. Investigating PIK3CA mutational status on cisplatin and radiation sensitivity in cervical cancer cell lines: Implications for PI3K inhibitor therapy. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A119.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.005
Threshold uncertainty score0.016

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0050.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.049
GPT teacher head0.335
Teacher spread0.286 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2015
Admission routes1
Has abstractyes

Explore more

Same venueMolecular Cancer TherapeuticsSame topicPI3K/AKT/mTOR signaling in cancerFrench-language works237,207